The human T-cell leukemia virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL) is incurable by currently known therapies. ATL samples and cell lines derived from ATL patients show restricted sensitivity to tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) and CD95 ligand (CD95L). We have recently shown that HTLV-1-infected cells express elevated levels of cellular caspase-8 FLICE-inhibitory protein (c-FLIP) conferring resistance to receptor-mediated apoptosis. This finding underscores the demand to develop new strategies for treatment of ATL. In this study, we show that the naturally occurring herbal compound Rocaglamide (Roc) sensitizes CD95L-and TRAIL-induced apoptosis in HTLV-1-infected cells by downregulation of c-FLIP expression. Investigation of the molecular mechanism of Roc-mediated downregulation of c-FLIP revealed that it inhibits phosphorylation of the translation initiation factor 4E (eIF4E), a key factor that controls the rate-limiting step of translation, through inhibition of the MEK-ERK-MNK1 signaling pathway. This event prevents de novo synthesis of short-lived proteins such as c-FLIP in HTLV-1-infected cells. Our data suggest that Roc may serve as an adjuvant for TRAIL-based anticancer therapy.
Induction of apoptosis in tumor cells is one of the therapeutic strategies against different types of cancer. [1] [2] [3] Apoptosis may be induced through the mitochondrial (intrinsic) pathway or through death receptors of the tumor necrosis factor (TNF) receptor superfamily, such as CD95 (APO-1/Fas) and the TNF-related apoptosis-inducing ligand (TRAIL) receptors, TRAIL-R1 and TRAIL-R2. 3, 4 Intrinsic death stimuli (e.g., anticancer drugs) directly or indirectly activate the mitochondrial pathway resulting in the release of cytochrome c and sequential activation of caspases-9 and 3, finally leading to apoptosis. 2 The receptor-mediated apoptosis pathway is initiated by ligation of death receptors with their cognate ligands, such as TRAIL and CD95 ligand (CD95L), resulting in activation of caspases-8 and 10, which induces apoptosis by subsequent activation of the executioner caspase-3 or indirectly through the mitochondria by cleavage of the Bcl-2 family protein Bid, which induces cytochrome c release. 3, 4 One major negative regulator of receptor-mediated apoptosis is the cellular caspase-8 (FLICE)-inhibitory protein (c-FLIP), which blocks processing and activation of caspase-8 at the level of the death-inducing signaling complex. 4 TRAIL, in contrast to the CD95L, shows virtually no toxicity on normal cells and, therefore, is a promising anticancer agent that is currently under clinical trails. 3, 5, 6 Unfortunately, many cancer cells remain partially or completely resistant to TRAIL, and in some resistant cancers, TRAIL even stimulates survival and proliferation. 7, 8 The human T-cell leukemia virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL) is a malignancy of clonally proliferating infected mature CD4 þ T cells. 9 We and others have shown that primary HTLV-1-ATL samples and ATL cell lines derived from HTLV-1-infected patients are more resistant to TRAIL-and CD95L-mediated apoptosis compared with non-HTLV-1-infected leukemic cells. [10] [11] [12] Worldwide HTLV-1 has infected 15-20 million people. Patients have a poor prognosis with a survival range of less then 1 year after disease onset. So far, HTLV-1-associated ATL is incurable by presently known therapies. 9 Expression of the virus transactivator protein Tax has been found to correlate with resistance to TRAIL and CD95L. 10, 12 Recently, we and others have shown that HTLV-1 Tax increases c-FLIP expression, which is responsible for the resistance to receptor-mediated apoptosis. 12, 13 Downregulation of c-FLIP by siRNA has been shown to be sufficient to sensitize various types of cancer cells, including the HTLV-1-associated ATL to death ligands. 12, 13 Therefore, c-FLIP represents a promising therapeutic target, especially for TRAIL-based therapies.
c-FLIP expression is controlled at multiple levels. At the transcriptional level, c-FLIP is the target of the inducible transcription factors NF-kB and NF-AT. 14, 15 In addition, the extracellular-signal-regulated kinase (ERK) and the phosphatidylinositol 3-kinase (PI3K) both have been shown to regulate c-FLIP expression. [16] [17] [18] [19] [20] Furthermore, c-FLIP protein turnover has been shown to be actively regulated by ubiquitinmediated proteasomal degradation. 21, 22 Especially, the short form of c-FLIP proteins, c-FLIP S , contains a unique C terminus that confers its preferred ubiquitination and, thus, a considerably shorter half-life than the long form of c-FLIP (c-FLIP L ). 21 Activation of the stress-response c-Jun N-terminal protein kinase (JNK) may also promote c-FLIP L ubiquitination through phosphorylation of the E3 ubiquitin ligase Itch. 22, 23 We have previously shown that Rocaglamide (Roc), a naturally occurring herbal compound, derived from the traditional Chinese medicinal plant Aglaia (for reviews, see Proksch et al. 24 and Kim et al. 25 ), preferentially induces apoptosis in malignant but not normal proliferating lymphocytes. 26 This preference has been partially explained by its activation of the stress-response mitogen-activated protein kinases (MAPK) p38 and JNK in contrast to suppression of survival MAPK ERK activity in malignant, but not normal cells. 26 Recently, in vitro and an in vivo mouse T-cell leukemia model, we showed high toxicity to tumor cells and only minor toxicity towards normal cells, e.g., activated T cells. 26, 27 Toxicity and cell death is mediated through suppression of c-FLIP expression at the transcriptional level by blocking NF-AT activation. 27 Here, we further investigated whether Roc inhibits c-FLIP expression by additional mechanisms and whether it can be used as a sensitizer of receptor-mediated apoptosis. We show that Roc sensitizes resistant ATL cells to receptor (TRAIL-R1/2)-mediated apoptosis by translational suppression of c-FLIP through inactivation of the translation initiation factor 4E (eIF4E). Our studies demonstrate that Roc may serve as an adjuvant of TRAIL-based therapies in c-FLIP-overexpressing malignant cells.
Results
Roc inhibits c-FLIP expression. Recently, we have shown that Roc suppresses activation-induced expression of c-FLIP in leukemic T cells at the transcriptional level by downregulation of NF-AT activity. 27 In that study, we noticed that the basal level of c-FLIP expression (without activation) was also reduced upon Roc treatment. Thus, we asked whether Roc can sensitize ATL cells to receptor-mediated apoptosis through suppression of c-FLIP expression. To investigate this question, we randomly chose four different ATL cell lines derived from HTLV-1-infected ATL patients: SP, MT-2, CHAMP and ATL-3. All cell lines are characterized by the expression of the viral transactivator protein Tax (Figure 1a) , and are resistant to TRAIL-mediated apoptosis compared with non-HTLV-1-infected leukemic cell lines, e.g., Jurkat and CEM ( Figure 1b ). All ATL cell lines express TRAIL-R1 and TRAIL-R2 at levels comparable with those of CEM and Jurkat cells (Figure 1c (Figure 2c ). Roc treatment also did not affect the expression levels of the Tax protein (Figure 2c) . Downregulation of c-FLIP expression was also observed by another two Roc derivatives Roc-A and Roc-Q (data not shown). As controls, the expression levels of procaspase-8 and tubulin were unchanged.
Roc sensitizes CD95L-and TRAIL-mediated apoptosis in ATL, but not in normal T cells. As knocking-down of c-FLIP by an siRNA approach has been shown to sufficiently restore the sensibility of Tax-expressing leukemic cells to receptor-mediated apoptosis, 12, 13 we predicted that inhibition of c-FLIP expression by Roc would lead to sensitization of HTLV-1-infected ATL cells to receptor-mediated apoptosis. As expected, treatment of the ATL cells in the presence of Roc-AR synergistically increased CD95L-and TRAILinduced apoptotic cell death (Figure 3a) . In contrast, Roc-AR did not sensitize normal peripheral blood T cells to CD95L-and TRAIL-mediated apoptosis (Figure 3b ). The ability of Roc-AR to enhance receptor-mediated apoptosis was further demonstrated by western blot showing that the activity of caspase-8, the main caspase involved in the extrinsic death pathway, was enhanced by the combination treatment that could be observed as early as 4 h after treatment ( Figure 3c ). The sensitization is not due to enhanced expression of the receptors as Roc-AR did not influence cell surface expression levels of CD95 and TRAIL receptors after 12 h treatment (Supplementary Figure S1 ). These data demonstrate that Roc can sensitize HTLV-1-infected leukemic cells towards CD95L-and TRAIL-mediated apoptosis by downregulation of c-FLIP.
Roc inhibits protein synthesis. We first investigated whether Roc-AR inhibits c-FLIP mRNA expression in 25 Therefore, we carried out a 35 S-methionine incorporation assay to examine whether Roc-AR downregulates c-FLIP expression through inhibition of protein synthesis. In parallel, cycloheximide (CHX) was used as a control, which inhibits protein biosynthesis by the ribosomal machinery. 28 The experiment showed that Roc-AR strongly inhibited 35 S-methionine incorporation with an IC 50 of approximately 30 nM (Figure 4b ). These data suggest that Roc-AR may downregulate c-FLIP expression through inhibition of translation.
To further investigate whether Roc directly inhibits the protein synthesis machinery, we carried out an in vitro translation assay using a rabbit reticulocyte cell-free system. Luciferase mRNA was incubated with the rabbit reticulocyte lysate in the absence or presence of different concentrations of Roc-AR (0-200 nM) or CHX (0-200 ng/ml). Luciferase protein synthesis was quantified by luminescense.
The experiment showed that CHX blocked protein synthesis in a dose-and time-dependent manner (Figure 4c) . In contrast, 100 nM of Roc-AR, which was shown to completely block 35 S-methionine incorporation (Figure 4b ), showed no effect on protein synthesis in the rabbit reticulocyte cell-free system (Figure 4c ). These data indicate that Roc does not directly inhibit the translation machinery, but rather acts through inhibition of the signaling pathway that is required for translation.
Roc inhibits the MEK-ERK-MNK-eIF4E signaling pathway. Initiation of translation involves a highly regulated process. The rate-limiting step of translation is the binding of the initiation factor eIF4E to the mRNA 5 0 cap structure. 29 The activity of eIF4E is regulated by two major signaling pathways, the ERK and the PI3K pathway. [29] [30] [31] ERK phosphorylates the kinase Mnk, which in turn phosphorylates eIF4E. Phosphorylation of eIF4E increases its affinity for the 5 0 cap structure and thereby stimulates translation (schematically depicted in Figure 5a ). PI3K activates eIF4E through activation of the kinase mammalian target of rapamycin (mTOR). [29] [30] [31] mTOR activation disrupts the interaction between 4E-BP1 and eIF4E, allowing eIF4E to bind to the 5 0 cap structure (schematically depicted in Figure 5b ). Both, ERK and PI3K pathways have been shown to regulate c-FLIP expression. [17] [18] [19] [20] We have previously shown that Roc-A, a Roc derivative with a structure similar to Roc-AR, can downregulate ERK activity in different leukemic cell lines and in leukemic samples from patients. 26 To investigate whether Roc-AR could also inhibit the ERK pathway in HTLV-1-infected ATL cells, SP cells were treated with Roc-AR (100 nM) for different times, and the phosphorylation status of MEK1/2, ERK, MNK1 and eIF4E was analyzed by western blot. The experiments showed that Roc-AR inhibits the phosphorylation of MEK1/2, ERK, MNK and eIF4E and the inhibition could be detected as early as 30 min after Roc-AR treatment (Figure 5a ). We then investigated whether Roc-AR also interferes with the PI3K-mTOR pathway. The experiment showed that Roc-AR at a dose that inhibits c-FLIP protein expression did not inhibit mTOR phosphorylation (Figure 5b) . As a positive control, phosphorylation of mTOR was blocked by Rapamycin in a time-dependent manner (Figure 5b) . Therefore, Roc can inhibit protein synthesis, e.g., of c-FLIP by blocking the MEK-ERK-MNK-eIF4E signaling pathway.
To further investigate the role of the MEK-ERK-MNK signaling pathway in regulation of the receptor-mediated apoptosis, we carried out an experiment using specific inhibitors that target activities of MEK and ERK, respectively.
As expected, inhibition of MEK or ERK alone could sensitize TRAIL-induced apoptosis (Figure 5c ). Thus, Roc-mediated inhibition of the MEK-ERK signaling pathway contributes to sensitization of TRAIL-induced apoptosis in HTLV-associated ATL cells.
It has been shown that JNK can promote c-FLIP L ubiquitination and degradation through phosphorylation of the E3 ubiquitin ligase Itch. 22 We have previously shown that JNK can be transiently activated by Roc. 26, 27 Thus, Roc-mediated downregulation of c-FLIP L might also involve a JNK-mediated mechanism. To investigate this possibility, we carried out the experiment in the presence of the JNK-specific inhibitor SP600125. However, we did not see clear reversal of the Roc effect using different concentrations of SP600125 (Supplementary Figure S2) . This unresponsiveness to the JNK inhibitor may be explained by the fact that (1) turnover of c-FLIP L but not c-FLIP S is controlled by JNK activity. 22 Therefore, preventing degradation of c-FLIP L alone may not be sufficient to overcome Roc-mediated sensitization. (2) JNK is only transiently activated by Roc (0.5-2 h). 26 Thus, such short activation may not have a main role in degradation of c-FLIP L . To further confirm that downregulation of c-FLIP expression by Roc is regulated through inhibition of cap-dependent translation, we examined the effect of Roc on the expression of c-FLIP whose translation is regulated through IRES, a translation mechanism independent of cap-structure. 32 The experiments showed that Roc treatment resulted in the inhibition of the endogenous c- 
Discussion
Although TRAIL is a promising anticancer agent that kills various cancer cells with no toxicity to normal cells, many cancer cells remain resistant to TRAIL. For instance, most leukemias including HTLV-1-associated ATL show restricted sensitivity to TRAIL. 7 We and others have recently shown that HTLV-1 Tax, the major HTLV-1 protein with oncogenic potential, confers resistance to receptor-mediated apoptosis by enhancing c-FLIP expression. 12, 13 This underscores the demand of therapies with agents that can target c-FLIP expression to enhance the TRAIL-signalling pathway. In this study, we show that Roc-AR enhances TRAIL-mediated apoptosis in HTLV-1-infected ATL cells by downregulation of c-FLIP expression.
Two main signaling pathways, the Ras-ERK and the PI3K pathway, have been implicated in controlling c-FLIP expression. [16] [17] [18] [19] [20] The Ras-ERK pathway is also the target of the HTLV-1 oncogenic protein Tax. 33, 34 Recently, Ras-ERK signaling was shown to be particularly important for Taxmediated protection of cells from apoptosis. 35 Our study demonstrates that Roc can block the Ras-ERK signaling pathway and thereby downregulate c-FLIP expression through inhibition of eIF4E function, a key factor that controls the rate-limiting step of translation. 29 Although inhibition of eIF4E function will lead to inhibition of translation in general, only the expression levels of c-FLIP proteins were shown to be downregulated by Roc treatment. No suppression of the expression levels of Bcl-2, Bcl-xL and Tax was seen in Roc-treated ATL cells. It is known that c-FLIP turnover is actively regulated by a mechanism of ubiquitinmediated proteasomal degradation and, therefore, c-FLIP has a short half-life. 21, 22 Especially, c-FLIP S protein contains a unique C terminus that confers its preferred ubiquitinilation and, thus, has an even shorter half-life than the c-FLIP L . 21 Thus, inhibition of de novo protein synthesis by Roc leads to downregulation of only short-lived proteins, such as c-FLIP, especially c-FLIP S . c-FLIP expression has also been shown to be controlled by the PI3K pathway. 19, 20 However, in our experiments, Roc did not show an inhibitory effect on the PI3K pathway.
So far, HTLV-1-associated ATL is incurable by the presently known therapies. 9 As TRAIL is a promising anticancer agent, this study is aimed to explore an approach to overcome TRAIL-resistance in HTLV-1-associated ATL cells. Sensitivity and resistance of HTLV-1-associated ATL cells to other chemotherapeutic drugs are another important issue. As Roc inhibits the MEK-ERK signaling pathway, we speculate that combinations of Roc with other chemotherapeutic drugs that target the signaling pathways different from Roc could have beneficial effects on the treatment. Future studies are planned to investigate this issue.
In summary, we demonstrate that Roc inhibits expression of c-FLIP at the translational level, and thereby breaks TRAIL resistance in HTLV-1-infected ATL cells. We also show that Roc does not directly inhibit the translation machinery, instead Roc inhibits the ERK pathway leading to inhibition of phosphorylation of eIF4E, a key factor for controlling the rate-limiting step of translation. So far, therapy shows only very limited benefit to HTLV-1-associated ATL patients because of resistance of the tumor cells to apoptosis. Our study raises the possibility to develop Roc as a TRAIL adjuvant for treatment of HTLV-1-associated ATL. As many tumors express elevated levels of c-FLIP and siRNA, knockdown of c-FLIP has been shown to sensitize these cells to death ligands; Roc may also be used to enhance the success of TRAIL therapy in c-FLIP-overexpressing cancers.
Materials and Methods
Cells and cell cultures. The human malignant cell lines used in this study are the human leukemic T-cell lines CEM and Jurkat (J16) and the HTLV-1 ATL-derived cell lines SP, MT-2, CHAMP and ATL-3. Human peripheral blood T cells were prepared as described previously 27 and were more than 90% CD3 þ . All cells were cultured in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY, USA) supplemented with 10% FCS, 50 mg/ml gentamicin (GIBCO Laboratories), 6 mM HEPES (GIBCO Laboratories, 1 M solution) and 2 mM L-glutamine (GIBCO Laboratories, 200 mM solution) at 371C and 5% CO 2 .
Determination of apoptosis. Cells were plated in triplicates and treated for the indicated periods of time at 371C with different doses of Roc-AR (498% pure, Western blot analysis. For each sample, 1 Â 10 7 cells were lysed as described previously. 26 Equal amounts of proteins were separated on 7.5-13% SDS-PAGE depending on the molecular sizes of the proteins, blotted onto a nitrocellulose membrane (Amersham Biosciences, Little Chalfon, UK) and blocked with 5% non-fat dry milk in PBS/Tween (0.05% Tween-20 in PBS). The following antibodies were used: anti-caspase-3 polyclonal antibody (Cell Signaling), anti-ERK1 and antiphospho-ERK (Cell Signaling, Danvers, MA, USA), anti-MEK and anti-phospho MEK antibody (Cell Signaling), anti-mTOR (2972) and anti-phospho-mTOR (2971) (Cell Signaling), anti-Mnk1 (C-20) (Santa Cruz Biotechnology, Heidelberg, Germany), antiphospho-Mnk1 (2111) (Cell Signaling), anti-elF4E (9742) and anti-phospho-elF4E (9742) (Cell Signaling), anti-actin, anti-tubulin (Sigma-Aldrich, St. Louis, MO, USA), anti-TRAIL-R1-R4 (Alexis Biochemicals) and anti-Tax (hybridomas, clone 168B17-46-34, NIH AIDS Research, NIH, Rockville, MD, USA). The caspase-8 mAb C15 (mouse IgG2b) recognizes the p18 subunit of caspase-8, the c-FLIP mAb NF6, the agonistic anti-CD95 mAb were generated in our laboratory as described previously. 27 For stripping, blots were incubated for 30 min in a buffer containing 62.5 mM Tris/HCl, pH 6.8, 2% SDS and 100 mM b-mercaptoethanol at 561C. The blots were washed six times for 10 min in PBS/Tween and blocked again in 5% non-fat dry milk.
RNA isolation and quantitative real-time PCR. Extraction of total cellular RNA was performed using the NucleoSpin RNAII (Macherey-Nagel, Düren, Germany) extraction kit with 1 Â 10 7 cells per preparation according to the manufacturer's instructions. One mg of RNA was reverse transcribed into cDNA with MuLV reverse transcriptase (Roche, Mannheim, Germany) in the presence of 50 mM oligo-d(T) and 200 nM dNTPs at 421C for 45 min. Aliquots (1/4) of the resulting cDNA were then used as templates for PCR. The primers and conditions used for quantitative real-time PCR for c-FLIP L , c-FLIP S and b-actin (used as an internal standard) were described previously. 12 In vivo protein synthesis assays. Protein synthesis was estimated by measuring the amount of incorporated 35 S-methionine. Briefly, cells (1 Â 10 6 ) were incubated for 2 h with 1 ml of methionine-free medium in a 24-well plate. Then 7 mCi pro well of 35 S protein-labeling mix (PerkinElmer, Waltham, MA, USA) was added and cells were treated with different drugs as indicated. After incubation, cells were washed twice with PBS and lysed in ice-cold RIPA-lysis buffer for 15 min on ice and centrifuged (20 min, 13 000 r.p.m.). Four ml of each lysate was loaded on a filter paper, followed by precipitation with 10% trichloroacetic acid (TCA) by incubating the filter paper three times in TCA precipitation buffer for 5 min. After drying, the filter papers were incubated in 1 ml of Liquid Scintillation Cocktail solution (Beckman coulter, Brea, CA, USA) and radioactivity was determined with Liquid Scintillation counting.
In vitro translation assays. For the in vitro translation assay, the rabbit reticulocyte lysate system was used according to the manufacturer's instructions (Promega Corp., Mannheim, Germany). Briefly, 35 ml cell-free rabbit reticulocyte lysate was incubated with 1 mg luciferase mRNA at 301C in the absence or presence of different concentrations of Roc-AR (0-200 nM) or CHX (0-200 ng/ml) for the indicated times. Synthesis of luciferase protein was quantified by luciferase activity with a luminometer (Duolumat LB9507, Berthold, Wildbach, Germany).
Cell surface staining receptors. For analysis of surface expression levels of CD95 and TRAIL receptors, cells (5 Â 10 5 ) were washed with PBS and incubated with 1 mg/ml of corresponding antibodies for 30 min at 41C, washed with PBS and incubated for 30 min with phycoerythrin-conjugated goat anti-mouse antibody (Dianova, Duabiva, Hamburg, Germany), and analyzed by flow cytometry with a FACScan Cytometer (Becton Dickinson, Heidelberg, Germany). The following anti-TRAIL receptor antibodies were used: HS101 (TRAIL-R1), HS201 (TRAIL-R2), HS301 (Dc-R1) and HS402 (Dc-R2) (Alexis). The CD95 antibody is anti-APO-1 produced by our laboratory. 27 Plasmid and transfection. The GFP-IRES-c-FLIP L plasmid expressing the 55 kDa FLIP L protein under the control of IRES was constructed previously. 36 Transient transfection was carried out with the polyethylenimine (PEI, MW 25 000) (Sigma, Cat.: 40.872-7) based method. Briefly, plasmid DNA was suspended in Opti-MEM medium (GIBCO laboratories, Grand Island, NY, USA; Cat.: 51985) in a final concentration of 10 mg/ml, and PEI was suspended in Opti-MEM in a final concentration of 20 mg/ml. Before transfection, the plasmid and PEI solution were mixed by a 1 : 1 volume ratio and incubated at RT for 20 min to allow DNA/PEI complex formation. Three ml of DNA/PEI complex were drop-wise added into 10 cm cell culture dish with 50-70% confluence of growth. Cells were then cultured at 371C until harvest.
